BIOVECTRA, a part of Agilent Technologies Inc., is a leading North American CDMO specializing in biologics, mRNA therapeutics, and complex chemistry, proudly announces it is the recipient of the 2025 Outsourced Pharma CDMO Leadership Award in the category of biologics.
European Commission greenlights Mirati’s Krazati in KRAS-mutated NSCLC – Pharmaceutical Technology
Share this article Krazati is forecast to generate $1.24bn in sales in 2029, according to GlobalData. Credit: gorodenkoff via Getty Images. Mirati Therapeutics has received